Application of c22orf41 as a tumor marker in pancreatic cancer

A tumor marker, pancreatic cancer technology, applied in the field of genetic engineering, can solve problems such as difficulty in early diagnosis, and achieve far-reaching clinical significance.

Active Publication Date: 2021-03-05
PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently available methods for diagnosing symptomatic pancreatic cancer are mainly imaging: computed tomography (CT), endoscopic ultrasonography (EUS), endoscopic retrograde cholangiopancreatography (ERCP), but early diagnosis is still very difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of c22orf41 as a tumor marker in pancreatic cancer
  • Application of c22orf41 as a tumor marker in pancreatic cancer
  • Application of c22orf41 as a tumor marker in pancreatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Survival analysis of pancreatic cancer based on TCGA database information Screening related genes

[0031] 1. Screening of clinical information

[0032] The clinical information of pancreatic cancer patients in the TCGA database was retrieved. As of December 10, 2015, a total of 185 clinical cases of pancreatic cancer were recorded in the TCGA database. These data were screened, and a total of 160 patients were included in the study. Patients with medical history of other malignancies, who had received radiotherapy or chemotherapy were excluded during screening, and patients included in the study were required to contain clinical information and mRNA data.

[0033] 2. Survival study sample statistics

[0034] The statistical results of the survival time of 160 patients with pancreatic cancer are shown in the following table:

[0035] Table 1 Survival time statistics of 160 patients with pancreatic cancer

[0036]

[0037] 3. Research plan for survival a...

Embodiment 2

[0043] Example 2 RT-PCR Detection of the Expression of Gene C22orf41 in Pancreatic Cancer and Paracancerous Tissues

[0044] 1. Materials

[0045] 1.1 Histopathological specimens

[0046] Tissues from 20 patients with pancreatic cancer who underwent surgical resection and were confirmed by pathological examination and corresponding paracancerous tissue samples were collected. Paracancerous tissue was defined as pancreatic tissue beyond 3 cm from the tumor edge. The samples were collected from patients who were diagnosed with pancreatic cancer and underwent surgical resection at Peking Union Medical College Hospital from October 2014 to December 2016. Immediately after surgical resection of pancreatic cancer tissue, under the guidance of pathologists, pancreatic cancer and paracancerous tissues were taken and placed in liquid nitrogen, and stored in a -80°C low-temperature refrigerator after serial numbering.

[0047] 1.2 The inclusion criteria are as follows:

[0048] (1) C...

Embodiment 3

[0078] Example 3 Effect of silencing C22orf41 expression on the proliferation of pancreatic cancer cells

[0079] 1. Design of shRNA sequence

[0080]For the target gene sequence of the target gene, use the RNA interference sequence design principles provided on the Pubmed website to design multiple RNA interference target sequences, and perform evaluation and determination based on relevant design experience and design software. The siRNA of the three RNA interference target sequences, simultaneously Select the scramble sequence recognized in RNAi design as a control, and the sequence is shown in Table 3: the scramble sequence is shown in SEQ ID NO.5, the target sequence of interference 1 is shown in SEQ ID NO.6, and the target sequence of interference 2 is shown in SEQ ID As shown in NO.7, the target sequence of interference 3 is shown in SEQ ID NO.8. According to the characteristics of the pLKO.1-TRC cloning vector, the DNA sequence of the siRNA and its corresponding compl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pancreatic cancer-related tumor marker C22orf41, and confirms that the C22orf41 gene is highly expressed in pancreatic cancer cancerous tissue cells. The present invention also provides the application of the kit for detecting the expression level of C22orf41 in the detection, diagnosis or prognosis of pancreatic cancer. The invention uses RNAi technology to interfere with C22orf41 gene to inhibit the proliferation of pancreatic cancer cells, confirms that C22orf41 can be used as a molecular target of targeted therapy, and provides a drug and a drug composition for inhibiting the proliferation of pancreatic cancer cells. The pancreatic cancer-related tumor marker C22orf41 of the present invention has potential value as a diagnostic detection, prognostic evaluation and therapeutic target, and has far-reaching clinical significance and important prospect of popularization and application.

Description

technical field [0001] The invention relates to the field of genetic engineering, in particular to the application of C22orf41 as a pancreatic cancer tumor marker. Background technique [0002] Pancreatic cancer is one of the deadliest cancers in the world, with a 5-year survival rate of less than 5%. The main reasons for the poor prognosis of pancreatic cancer are the insidious onset of pancreatic cancer, delayed diagnosis, early distant metastasis, strong local invasiveness, and lack of effective therapeutic drugs. Currently, surgical resection is considered the only definitive and effective treatment. Since pancreatic cancer is often found with metastasis, radical surgery cannot be achieved in most cases. So far, only about 20% of pancreatic cancer patients can undergo radical resection, and even in these patients, the 5-year survival rate is still very low due to early metastasis or recurrence. Currently available methods for diagnosing symptomatic pancreatic cancer a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886G01N33/574A61K45/00A61P35/00
CPCA61K45/00A61P35/00C12Q1/6886C12Q2600/118C12Q2600/158G01N33/57438G01N33/57484
Inventor 王文泽石秀玉肖雨庞钧译张明梁智勇
Owner PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap